Monday, May 16

7:00 p.m.–8:00 p.m.

Opening Keynote Session
Metropolitan Ballroom 1

Welcome Remarks
Session Chairperson: Stephen W. Fesik, Vanderbilt University School of Medicine, Nashville, TN

Keynote Address
Metropolitan Ballroom 1

The discovery of next-generation cancer targets and therapeutics
William R. Sellers, Novartis Institutes for BioMedical Research, Cambridge, MA

8:00 p.m. – 10:00 p.m.

Welcome Reception
Metropolitan Ballroom 2-4

Tuesday, May 17

7:00 a.m.–8:00 a.m.

Continental Breakfast
Metropolitan Ballroom 5-7
If applicable, please follow signs for Networking Roundtables.

8:00 a.m.–10:00 a.m.

Plenary Session 1: Targeting Programmed Cell Death and Autophagy
Metropolitan Ballroom 1
Session Chairperson: William R. Sellers, Novartis Institutes for BioMedical Research, Cambridge, MA

8:00 a.m.–8:30 a.m.
Mcl-1 inhibitors for the treatment of cancer
Stephen W. Fesik, Vanderbilt University School of Medicine, Nashville, TN

8:30 a.m.–9:00 a.m.
Mechanistic studies of IAP inhibitors
Wayne J. Fairbrother, Genentech, Inc., South San Francisco, CA

9:00 a.m.–9:30 a.m.
Pharmacological intervention in p53 regulation by inhibitors of MDM2 and ATM
Lyubomir T. Vassilev, EMD Serono R&D Institute, Inc., Billerica, MA

9:30 a.m.–10:00 a.m.
Autophagy prevents fatal nucleotide pool depletion in Ras-driven cancer cells
Eileen P. White, Rutgers-The Cancer Institute of New Jersey, New Brunswick, NJ

10:00 a.m.–10:30 a.m.

Break
Metropolitan Ballroom Pre-Function

10:30 a.m.-12:30 p.m.	**Plenary Session 2: Targeting Pathway Addiction and Resistance** Metropolitan Ballroom 1 **Session Chairperson: Paul Workman,** The Institute of Cancer Research, London, England
10:30 a.m.-11:00 a.m.	Genomic approaches to drug discovery **Todd R. Golub,** Broad Institute of MIT and Harvard, Cambridge, MA
11:00 a.m.-11:30 a.m.	Addiction of prostate cancer to androgen receptor **Yan Dong,** Tulane University, New Orleans, LA
11:30 a.m.-12:00 p.m.	Therapeutic resistance and feedback loops **Jean J. Zhao,** Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA
12:00 p.m.-12:30 p.m.	Non-mutational resistance to anti-cancer drugs **Jeffrey Settleman,** Calico Life Sciences, South San Francisco, CA
12:30 p.m.-3:00 p.m.	**Poster Session A with Lunch** Metropolitan Ballroom 2-4 (Posters) Metropolitan Ballroom 5-7 (Lunch)
3:00 p.m.-5:00 p.m.	**Plenary Session 3: Targeting Genomic Instability** Metropolitan Ballroom 1 **Session Chairperson: Frank McCormick,** UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
3:00 p.m.-3:40 p.m.	Targeting the DNA damage response in cancer: Progress in the clinic **Timothy A. Yap,** Royal Marsden Hospital and The Institute of Cancer Research, Sutton, England
3:40 p.m.-4:20 p.m.	Discovery and characterization of potent and selective inhibitors of ATR kinase as anti-cancer agents **John Pollard,** Vertex Pharmaceuticals (Europe) Ltd., Abingdon, England
4:20 p.m.-5:00 p.m.	CHK1 inhibitors: From concept to clinic **Michelle D. Garrett,** University of Kent, Canterbury, England
5:00 p.m.	**Evening on Own**

Wednesday, May 18

7:00 a.m.-8:00 a.m.	**Continental Breakfast** Metropolitan Ballroom 5-7 If applicable, please follow signs for Networking Rountables.
8:00 a.m.-10:00 a.m.	**Plenary Session 4: Targeting Multiple Hallmarks of Cancer** Metropolitan Ballroom 1 **Session Chairperson: William G. Kaelin, Jr.,** Dana-Farber Cancer Institute, Boston, MA
8:00 a.m.-8:30 a.m.	Targeting Ras **Frank McCormick,** UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
8:30 a.m.-9:00 a.m.	Novel approaches for targeting MYC **William P. Tansey,** Vanderbilt University, Nashville, TN
9:00 a.m.-9:30 a.m.	Targeting molecular chaperone and stress pathways to hit multiple cancer hallmarks and overcome resistance **Paul Workman,** The Institute of Cancer Research, London, England
9:30 a.m.-9:45 a.m.	IACS-010759 a novel inhibitor of oxidative phosphorylation advancing into first-in-human studies to exploit metabolic vulnerabilities* **Philip Jones,** The University of Texas MD Anderson Cancer Center, Houston, TX
9:45 a.m.-10:00 a.m.	Towards a cancer dependency map* **Aviad Tsherniak,** Broad Institute of MIT and Harvard, Cambridge, MA
10:00 a.m.-10:30 a.m.	**Break** Metropolitan Ballroom Pre-Function
10:30 a.m.-12:30 p.m.	**Plenary Session 5: Immunotherapy (Part 1)** Metropolitan Ballroom 1 **Session Chairperson: Jane Grogan,** Genentech Inc., South San Francisco, CA
10:30 a.m.-11:00 a.m.	Adoptive T cell therapy **Carl H. June,** Abramson Cancer Center of University of Pennsylvania, Philadelphia, PA
11:00 a.m.-11:30 a.m.	Building better T cells for targeting and eliminating tumors **Philip D. Greenberg,** Fred Hutchinson Cancer Research Center and University of Washington, Seattle, WA
11:30 a.m.-12:00 p.m.	Novel insights into T cell recognition and regulation at the tumor site **Andrew J.S. Furness,** UCL Cancer Institute and Royal Marsden Hospital, London, United Kingdom
12:00 p.m.-12:30 p.m.	Targeting molecules mediating the dialogue between epithelial cells and local T cells **Adrian Hayday,** The Francis Crick Institute, London, England

*Short talks from proffered abstracts.

12:30 p.m.–3:00 p.m. **Lunch on Own/Free Time**

3:00 p.m.–5:00 p.m. **Plenary Session 6: Immunotherapy (Part 2)**
Metropolitan Ballroom 1
Session Chairperson: Carl H. June, Abramson Cancer Center of University of Pennsylvania, Philadelphia, PA

3:00 p.m.–3:30 p.m. CTLA4 antibodies and beyond
James P. Allison, The University of Texas MD Anderson Cancer Center, Houston, TX

3:30 p.m.–4:00 p.m. The immunoreceptor TIGIT limits anti-tumor T cell responses
Jane Grogan, Genentech Inc., South San Francisco, CA

4:00 p.m.–4:30 p.m. Enhancing anti-tumor immunity through selective inhibition of IDO11†
Reid Huber, Incyte Corporation, Wilmington, DE

4:30 p.m.–4:45 p.m. Molecular characterization of in vitro exhausted T cells*†
William Hastings, Novartis Institute for Biomedical Research, Cambridge, MA

4:45 p.m.–5:00 p.m. Small molecule-mediated activation of Ras elicits inhibition of MAPK and PI3K signaling though pathway feedback*
Jennifer E. Howes, Vanderbilt University, Nashville, TN

5:00 p.m.–7:30 p.m. **Poster Session B and Reception**
Metropolitan Ballroom 2-4

7:30 p.m. **Evening on Own**

Thursday, May 19

7:00 a.m.–8:00 a.m. **Continental Breakfast**
Metropolitan Ballroom 5-7
If applicable, please follow signs for Networking Rountables.

8:00 a.m.–10:00 a.m. **Plenary Session 7: Targeting Epigenetics**
Metropolitan Ballroom 1
Session Chairperson: Jeffrey Settleman, Calico Life Sciences, South San Francisco, CA

8:00 a.m.–8:30 a.m. Transcriptional regulators as cancer dependencies
Christopher R. Vakoc, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY

8:30 a.m.–9:00 a.m. Targeting cancers with deletion of the p16/p14 tumor suppressor locus
Kevin Marks, Agios Pharmaceuticals Inc., Cambridge, MA

*Short talks from proffered abstracts
†Not eligible for CME credit

9:00 a.m.-9:30 a.m.	Targeted inhibition of the menin-MLL interaction in cancer **Jolanta E. Grembecka,** University of Michigan, Ann Arbor, MI
9:30 a.m.-10:00 a.m.	Protein methyltransferase inhibitors as precision cancer therapeutics: From bench to bedside to bench **Robert A. Copeland,** Epizyme, Inc., Cambridge, MA
10:00 a.m.-10:15 a.m.	**Break** Metropolitan Ballroom Pre-Function
10:15 a.m.-12:15 p.m.	**Plenary Session 8: Targeting Oncoproteins for Degradation** Metropolitan Ballroom 1 **Session Chairperson: Robert A. Copeland,** Epizyme, Inc., Cambridge, MA
10:15 a.m.-10:45 a.m.	PROTACs as a therapeutic strategy to induce protein degradation **Craig M. Crews,** Yale University, New Haven, CT
10:45 a.m.-11:15 a.m.	Targeting undruggable proteins for degradation with small molecules **William G. Kaelin, Jr.,** Dana-Farber Cancer Institute, Boston, MA
11:15 a.m.-11:45 a.m.	Targeting hormone receptors for degradation: Nuclear receptor downregulation as a therapeutic approach in cancer **Donald P. McDonnell,** Duke University Medical Center, Durham, NC
11:45 a.m.-12:15 p.m.	Phthalimide conjugation as a strategy for targeted protein degradation **Georg E. Winter,** Dana-Farber Cancer Institute, Boston, MA
12:15 p.m.	**Departure**